Chongqing Genrix Biopharmaceutical Co., Ltd. (SHA:688443)

China flag China · Delayed Price · Currency is CNY
26.84
+1.22 (4.76%)
At close: Mar 6, 2026
Market Cap9.84B +7.4%
Revenue (ttm)230.72M +666.6%
Net Income-536.22M
EPS-1.47
Shares Out366.68M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume4,104,414
Average Volume2,965,061
Open25.61
Previous Close25.62
Day's Range25.56 - 27.09
52-Week Range22.89 - 37.88
Beta0.71
RSI42.09
Earnings DateApr 30, 2026

About SHA:688443

Chongqing Genrix Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs in China. It develops GR1501, a monoclonal antibody for the treatment of axial spondylarthritis; GR1801, an anti-rabies virus G protein bispecific antibody; GR1802, an anti-IL-4Ra monoclonal antibody; GR1603, a monoclonal antibody for systemic lupus erythematosus; GR2002 an anti-TSLP bispecific antibody; WM1R3, a family receptor bispecific antibody; GR2001, a monoclonal antibody; GR2201, a mo... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 793
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688443
Full Company Profile

Financial Performance

In 2025, SHA:688443's revenue was 230.72 million, an increase of 666.65% compared to the previous year's 30.09 million. Losses were -536.22 million, -32.74% less than in 2024.

Financial Statements